166 results about "Dyskinesia" patented technology

The present invention discloses a dyskinesia rehabilitation training method and system based on electroencephalogram signal recognition; the method includes: the convolutional neural network is used to recognize the electroencephalogram signal, analyze the patient's motor intention, convert the motor intention into a control instruction for the exoskeleton device, drive the patient's limb movement by controlling the movement of the exoskeleton device, and assist the patient to complete the movement disorder rehabilitation training. In this method, the self-attention mechanism and self-distillation training were used to establish an electroencephalogram signal recognition model, analyzing the patient's motor intention to help motor nerve remodeling, which broke the passive and single problem of traditional rehabilitation methods, realized active rehabilitation of patients, and significantly improved the rehabilitation efficacy.

The invention belongs to the technical field of cerebral apoplexy rehabilitation medicine, and relates to evaluation of myoelectric medicine, in particular to an HD-sEMG-based evaluation method and evaluation system for hand dyskinesia of a cerebral apoplexy hemiplegia patient. According to the invention, the high-density surface myoelectricity data of the front arms of the healthy side and the affected side can be respectively collected when the stroke hemiplegia patient executes different hand actions, and the microscopic neuron characteristics are analyzed, so that the degree and progress of dyskinesia of the stroke hemiplegia patient can be accurately evaluated. Through statistical analysis of the number of motion units, the average discharge rate and the discharge mode, changes and rules of neurons in the rehabilitation process are revealed, the difference between the healthy side and the affected side is compared, and the motion function condition of the neurons is evaluated.

The invention discloses a Parkinson's dyskinesia individualized SCAN network positioning method based on a multi-modal image and deep learning. The method comprises the steps of obtaining multi-modal medical image data, preprocessing the multi-modal medical image data, obtaining a multi-modal structure image and functional connection data, and calculating a spontaneous neural activity index of a whole-brain voxel level; taking a priori brain region related to the spontaneous neural activity index and dyskinesia as a seed point, constructing a seed point voxel function connection graph representing individual brain function connection, and performing nonlinear feature fusion and extraction through the deep learning network model; the bilinear attention network is adopted to capture the interaction information of the feature data and the individual dyskinesia symptom which is significantly related, an individualized SCAN network positioning result is obtained, the structure-function coupling characteristics of the individual brain are comprehensively described, the cross-modal pathological features related to the dyskinesia can be more sensitively recognized, and the accuracy and accuracy of the diagnosis and treatment of the dyskinesia can be improved. And the accuracy and robustness of abnormal brain region detection are obviously improved.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention relates to the technical field of data processing, and discloses a gait rehabilitation evaluation method and system based on spatial-temporal characteristics of multi-modal data, a terminal and a storage medium, and the method comprises the steps: synchronously collecting myoelectricity, electroencephalogram and exoskeleton robot IMU signals of a dyskinesia crowd in a certain motion normal form in a specific period interval; a motion function scoring result of a doctor on a patient according to a scale is synchronously recorded, data preprocessing, channel selection and feature extraction are performed on myoelectricity, electroencephalogram and exoskeleton robot IMU signals, a model is established based on a neural network, motion evaluation is performed according to a fused feature array, and a motion function quantitative score is obtained; and the motion function state of the evaluated person is graded according to the score. According to the method, the multi-modal synchronous data rehabilitation evaluation model of the movement function of the dyskinesia crowd is constructed according to multiple information mining, and the movement function state of the evaluated person is rapidly evaluated, predicted and graded.

The invention discloses a gait intervention method, a music generation method, a device, a system, equipment and a medium for people suffering from dyskinesia diseases, and relates to the technical field of intelligent medical treatment. The method comprises the following steps: in the process of performing abnormal gait intervention treatment on a target object suffering from dyskinesia according to rhythmic music, acquiring multi-modal physiological data of the target object in real time, and dynamically determining a plurality of gait-related movement symptom characteristic indexes of the target object according to the multi-modal physiological data; determining music parameters at each moment in real time according to the multiple exercise symptom characteristic indexes; and dynamically adjusting notes of the rhythmic music at each moment according to the music parameters at each moment, and generating the rhythmic music adaptive to the current gait condition of the target object. According to the scheme, the rhythm music can be dynamically adjusted more comprehensively and individually, the current gait condition of the target object can be better met and adapted, and the effect of abnormal gait rehabilitation treatment, intervention and correction can be improved.

Disclosed herein are methods, pharmaceutical combinations, or kits for the prevention or treatment of extrapyramidal syndromes, for example, dyskinesia, dystonia, akathisia, or drug-induced Parkinsonism, with the administration of a therapeutic effective amount of Trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof.

Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for primary ciliary dyskinesia (PCD), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject.

The invention provides an application of a TRPML1 specific small-molecule inhibitor ML-SI3 in preparation of a drug for treating or preventing brain injury. The TRPML1 specific small-molecule inhibitor ML-SI3 has the beneficial effects that the TRPML1 specific small-molecule inhibitor ML-SI3 disclosed by the invention can be used for remarkably reducing the injury degree of neurons of rats with brain injury; the learning and memory ability of rats with brain injury is improved; the dyskinesia of rats suffering from brain injury is improved, and the brain function of the rats suffering from sudden cardiac arrest and cardiopulmonary resuscitation is comprehensively protected; the TRPML1 specific small-molecule inhibitor ML-SI3 provided by the invention provides a new medicine for protecting the brain function of a patient with sudden cardiac arrest, and has good market value and clinical application prospect.

The invention provides a rehabilitation training plan processing method, a brain-computer interface device and a storage medium, and relates to the technical field of brain-computer interfaces. According to the method, the motor imagery ability evaluation result of the target object is obtained mainly based on the electroencephalogram signal of the target object, that is, the motor imagery ability of different patients can be quantitatively evaluated according to the scheme; then, aiming at the two indexes of the motor imagery ability evaluation result and the dyskinesia level of the patient, a rehabilitation training plan is generated for the patient in a personalized manner, namely, the rehabilitation plan has the characteristics of pertinence, scientificity, reasonability and the like, so that the rehabilitation efficiency of the patient is greatly improved, and the rehabilitation time of the patient is saved; meanwhile, the use efficiency of the rehabilitation robot is improved, that is, the rehabilitation effect of the motor imagery therapy is better than that of a traditional rehabilitation method, and the problem that in the prior art, rehabilitation training is unreasonable in formulation is solved.

The present invention provides a method and system for classifying infant behavior characteristics based on deep learning, including: Step 1: Produce an infant video dataset, and classify and annotate time segments for the videos in the dataset; Step 2: Produce an infant key point dataset; Step 3: Preprocess the human key points of the infant video dataset; Step 4: Use a deep learning model to build an infant behavior classification model, send the human key point features of the infant video dataset into the infant behavior classification model, calculate the classification probability output by the model, the total loss between the output time segment and the label, and use the total loss for backpropagation to update the model parameters. After the model parameters converge, the training is completed; Step 5: Judge whether there is a dyskinesia in the video according to the classification probability of the classification branch, and obtain the time segment when there is a dyskinesia in the video. The present invention can detect whether an infant lacks dyskinesia and relieve the burden on doctors of having to watch infant movement videos for a long time.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

A combined neuromodulation and / or neurostimulation system for mitigating locomotor deficits of / or neuronal disorders, especially Parkinson's disease, said system comprises: at least one Deep Brain Stimulation System for providing Deep Brain Stimulation to brain tissue of a subject, at least one control unit, configured and adapted to provide stimulation data, at least one stimulation unit, operatively connected to the at least one control unit, the at least one stimulation unit being configured and adapted to deliver epidural electrical stimulation to the dorsal side of the spinal cord of said subject, and at least one implantable pulse generator, wherein the at least one stimulation unit includes one or more electrodes configured to be implanted epidurally, the one or more electrodes being operatively connected to the at least one IPG.

The invention belongs to the technical field of computer vision, and discloses an arm movement automatic evaluation system and method for dyskinesia of a cerebral palsy patient, and the system is characterized in that a data collection module carries out the movement data collection of the movement task of the arm of the patient through a smart phone camera; the posture estimation and key point detection module uses a posture estimation algorithm to automatically detect and track arm movement of a patient and recognize key points of a human body, and after coordinate data of the key points are obtained, data preprocessing is carried out; the muscular dyskinesia feature extraction module extracts muscular dyskinesia features from the motion data of the arm of the patient and constructs a corresponding feature set; the automatic scoring module uses a multi-layer feedforward neural network model to automatically calculate the score of the muscular dystonia based on the arm movement characteristics of the patient; the report generation module is used for generating an evaluation report. The method is suitable for arm movement evaluation of myodynia of cerebral palsy patients, and an objective, convenient and efficient evaluation tool is provided for clinicians.

The invention is a method for treating levodopa naïve patients with Parkinson's disease by orally administering a controlled release levodopa formulation twice a day to the levodopa naïve patient and the method provides an improvement of a patient's motor state as determined by patient's Parkinson's disease diary, provides a reduction of from about 10%-40% in the patient's tremor, dyskinesia, and / or mobility and / or provides a reduction in the patient's Movement Disorders Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores by at least 3 points.

The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.

The invention discloses a daily life activity ability assessment method and system based on a multi-branch space-time fusion network. The method comprises the steps of collecting motion data of a to-be-evaluated object, performing segmentation, noise reduction and standardization preprocessing, and extracting time-frequency domain features and motion deviation degree, motion similarity index and bilateral symmetry index provided by the invention; obtaining a uniform Bhattacharyya index scale score; and taking the motion feature data set and the clinical score as input, performing training based on a multi-branch space-time fusion algorithm, constructing a multi-task prediction model, and realizing automatic evaluation of the ADL. According to the method, the multi-branch space-time fusion network is innovatively introduced, the relevance between tasks is fully utilized, the spatial feature extraction capability is enhanced in combination with the graph neural network, adaptive fusion of the features is realized through a cross-layer interactive attention mechanism, the model prediction precision and evaluation reliability are remarkably improved, and the method is suitable for large-scale popularization and application. And an effective technical support is provided for rehabilitation evaluation and personalized treatment of patients with dyskinesia and disability and dementia.

The present disclosure relates to the use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease. In particular the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the THCV used is in the form of a botanically derived purified THCV. Alternatively, a synthetically produced THCV is used.

Provided herein are optionally substituted pyrazolylacetamides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating diseases or disorders, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania, tinnitus, neurodevelopmental diseases or disorders, a smooth muscle contractility disorder, Dravet syndrome, posttraumatic stress disorder (PTSD), with such compounds and pharmaceutical compositions.

The invention relates to the technical field of dyskinesia recognition, and discloses a dyskinesia recognition method and equipment for a Parkinson's disease based on wearable equipment, and the method comprises the following steps: S1, collecting historical data, and constructing a reference database of dyskinesia; s2, collecting motion data of a user, and obtaining basic motion parameters of the user; s3, based on the basic motion parameters of the user, screening a reference sample for the user from the reference database; s4, performing feature extraction on the motion data of the user to obtain a motion feature index of the user; s5, matching the motion characteristic indexes of the user and the reference sample to obtain a dyskinesia recognition result of the user; according to the invention, the accuracy and comprehensiveness of dyskinesia identification of the Parkinson's patient are improved.

The invention relates to the technical field of medicines, and discloses an adeno-associated virus (AAV) injection carrying an artificial chemical genetics receptor gene sequence, and a combinatorial chemical genetics scheme formed by the adeno-associated virus injection and a small molecule agonist quetiapine. Compared with the traditional chemical genetics, the medicine quetiapine with smaller clinical side effect is used as the activating agent for the first time, and a novel chemical genetics system with lower medication risk is developed. The system can effectively reduce the excitatory activity of neurons, avoids the medication risk caused by clozapine or other non-market traditional chemical genetics activators, and improves the feasibility of clinical transformation of the chemical genetics system. In the aspect of application of a novel or traditional chemical genetics system, the combined treatment scheme is applied to intervene in Parkinson's disease (PD) for the first time, abnormal activities of STN and related loops of PD patients can be inhibited, and the dyskinesia symptom can be remarkably improved.

The invention relates to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for treating Parkinson's disease, namely tremor syndrome of traditional Chinese medicine, which comprises the following raw materials by weight: 390-470g of liver calming and wind calming medicine, 140-160g of radix rehmanniae, 280-320g of radix paeoniae alba, 840-960g of first decoction medicine, 390-450g of blood activating and qi regulating and tendon and collateral dredging medicine, and 305-355g of antidote. The traditional Chinese medicine composition has remarkable effects of relaxing tendons and detoxifying, and calming endogenous wind and arresting fibrillation, can play a role in solving the problems of head shaking, limb tremor, muscle stiffness, dyskinesia and the like caused by liver wind internal movement and kidney deficiency and toxic damage of Parkinson's disease, and can nourish liver and kidney, relieve tendon and vessel contracture and relieve pain due to the synergistic effect of various traditional Chinese medicinal materials contained in the traditional Chinese medicine composition. The traditional Chinese medicine composition is especially suitable for Parkinson patients with liver-wind internal movement and kidney deficiency and toxicity loss, and can gradually improve the neurotransmitter level in the brain after being taken. The traditional Chinese medicine composition has an outstanding detoxification effect, can effectively remove accumulation of pathological products such as phlegm and blood stasis in the body of the Parkinson's disease patient, prevents phlegm and blood stasis from generating toxins, and can relieve medicine poison generated by long-term medicine taking of the patient.

The invention provides a stimulation parameter setting device for dyskinesia and an implantable closed-loop stimulation system, and belongs to the technical field of medical instruments. The device comprises a processor, wherein the processor is used for determining a variable-frequency mode or a constant-frequency mode according to the accelerated speed of a patient; when the frequency conversion mode is determined to be adopted, outputting a stimulation signal according to a preset frequency conversion stimulation parameter; and when the constant frequency mode is determined to be adopted, extracting an individual specific biomarker according to the physiological signal, obtaining a target threshold value, and adjusting a stimulation parameter according to a relationship between the individual specific biomarker and the target threshold value. The system comprises a processor and a controller. The controller is used for outputting stimulation signals according to the stimulation parameters.

A method of treating and attenuating L-DOPA-induced dyskinesia, comprising administering an effective dose of at least one pharmacological agent, e.g., vilazodone, having serotonin-specific reuptake inhibition (SSRI) and serotonin receptor 1A (5-HT1AR) partial agonism activity, in conjunction with L-DOPA. Other agents, such as an L-DOPA decarboxylase inhibitor, e.g., carbidopa, or other adjunct treatments may also be provided.

This disclosure relates to, inter alia, certain compounds, compositions, and pharmaceutical compositions thereof, that modulate the activity of the transporter protein vesicular monoamine transporter- 2 (VMAT2) and are directed to methods useful in the treatment of transporter protein vesicular monoamine transporter-2 mediated disorders, such as, neurological or psychiatric disease or disorders, including but not limited to, hyperkinetic movement disorders (e.g., tardive dyskinesia, Tourette's syndrome, Huntington's disease, tics, ataxia, chorea (such as, chorea associated with Huntington's disease), dystonia, hemifacial spasm, myoclonus, restless leg syndrome, and tremors). The disclosure further relates to synthetic methods and intermediates useful in the preparation of compounds.

The invention discloses a detection method for influence of PGRN regulation on cerebellar synaptic development of ASD rats, and relates to the technical field of autism spectrum disorders. The method specifically comprises the following steps: step 1, breeding an experimental rat; 60 Sprague-Dawley rats in the childbearing age are purchased, the female-male ratio is 2: 1, the rats freely eat and drink water, and the rats are fed for three to five weeks; step 2, preparing a VPA induced ASD rat model; experimental rats are subjected to fertilization culture, female rats are randomly divided into two groups after being fertilized for 12.5 days, a VPA solution is injected into the VPA group through the abdominal cavity, and sterile normal saline with the same volume is injected into the control group. The detection method shows that the PGRN can obviously relieve VPA-induced dyskinesia and autism-like behaviors of ASD rats and relieve cerebellar Purkinje cell synaptic dysplasia, and the mechanism of the PGRN is possibly related to inhibition of the PGRN on lysosomal functions and autophagy activities in cerebells of the ASD rats.

The invention provides a viscose dispersing type transdermal patch of a VMAT2 (Vitamin Matrix Activator 2) inhibitor 11-P4S. The transdermal patch is composed of a backing layer, a drug-containing substrate layer and an anti-sticking layer, wherein the drug-containing layer comprises 11-P4S free alkali and pharmaceutically acceptable salts thereof, a polyacrylate pressure-sensitive adhesive, a crystallization inhibitor, a transdermal absorption enhancer and an antioxidant. The viscose dispersing type transdermal patch can continuously release drugs within 24 hours, is stable in drug release, high in bioavailability and good in safety, can greatly improve the medication compliance and medication convenience of a patient with delayed dyskinesia (TD) on the basis of ensuring the clinical curative effect, reduces the nursing burden of nursing personnel, and is suitable for treating TD diseases.

The application relates to the medical technical field, in particular to application of neoline in treatment of Parkinson's disease. 19 The C 19 The type-II diterpene alkaloid neoline can significantly improve movement disorder in a MPTP-induced Parkinson's disease model mouse, the drug efficacy is equivalent to that of the positive drug madopar, the effective dose is much lower than that of the positive drug, the administration mode is oral administration, drug compliance and use convenience are good, and the neoline can be used for development of anti-Parkinson's disease drugs.